Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-1335

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression ; day:23 ; month:7 ; year:2020 ; pages:1-7
Journal of cancer research and clinical oncology ; (23.7.2020), 1-7

Creator: Masuda, Ken
Horinouchi, Hidehito
Tanaka, Midori
Higashiyama, Ryoko
Shinno, Yuki
Sato, Jun
Matsumoto, Yuji
Okuma, Yusuke
Yoshida, Tatsuya
Goto, Yasushi
Yamamoto, Noboru
Ohe, Yuichiro

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00432-020-03329-0

URN: urn:nbn:de:101:1-2020091619302874780411

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Masuda, Ken
Horinouchi, Hidehito
Tanaka, Midori
Higashiyama, Ryoko
Shinno, Yuki
Sato, Jun
Matsumoto, Yuji
Okuma, Yusuke
Yoshida, Tatsuya
Goto, Yasushi
Yamamoto, Noboru
Ohe, Yuichiro
SpringerLink (Online service)

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy

Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

Related objects

Reset password